Accelerating GLP-1 Drug Development: How Metsera, Certara & Altasciences Reached Phase 2 Case Study Accelerating GLP-1 Drug Development: How Metsera, Certara & Altasciences Reached Phase 2 See how Metsera, Certara, and Altasciences built an integrated MIDD partnership to advance GLP-1 programs…CertaraNovember 12, 2026
Bridging Oncology and Autoimmune Disease: Using QSP to Select T-Cell Engager Doses by CRS Risk and Efficacy Poster Bridging Oncology and Autoimmune Disease: Using QSP to Select T-Cell Engager Doses by CRS Risk and Efficacy Explore how QSP modeling informs T-cell engager dose selection for autoimmune diseases, balancing efficacy and…Piet van der GraafOctober 26, 2026
2nd Model-Informed Drug Development Summit Conference 2nd Model-Informed Drug Development Summit –sarah CarrOctober 13, 2026
From Data to Decisions: Getting More from Clinical Trial Evidence Webinar From Data to Decisions: Getting More from Clinical Trial Evidence Matt Zierhut, PhD MBAOctober 13, 2026
Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers Publication Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers A semi-mechanistic population PK model characterizes sorfequiline and its active M3 metabolite to support DDI…CertaraSeptember 18, 2026
A Best Practice Guide to Validation in Clinical Data Management Guide A Best Practice Guide to Validation in Clinical Data Management Learn best practices for software validation in research settings with this guide to validation in…Danielle PillsburySeptember 2, 2026
A glimpse into the future of model-informed drug discovery and development Publication A glimpse into the future of model-informed drug discovery and development Explore the future of Model-Informed Drug Development (MIDD), including advances in pharmacometrics, PBPK, QSP, precision…CertaraAugust 28, 2026
Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology Publication Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology Explore how model-based tumor growth inhibition metrics can support earlier Go/No-Go decisions and pivotal trial…CertaraAugust 28, 2026
De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA) Case Study De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA) Learn how Model-based meta-analysis (MBMA) helped optimize Phase 3 trial design, dose selection, and development…Danielle PillsburyAugust 28, 2026
Medtech market access: why strategy can’t wait for regulatory approval Blog Medtech market access: why strategy can’t wait for regulatory approval Medtech market access strategy must start long before approval. See how medical device reimbursement pathways…Eduardo UrbinaAugust 26, 2026